Gsa Capital Partners LLP Aerie Pharmaceuticals Inc Transaction History

Gsa Capital Partners LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 11, 2020	SELL	$12.0 - $16.13 $276,072 - $371,086	-23,006 Closed	0 $0
Q1 2020 May 12, 2020	BUY	$11.84 - $25.52 $272,391 - $587,113	23,006 New	23,006 $311,000
Q4 2019 Feb 12, 2020	SELL	$17.72 - $25.1 $218,115 - $308,955	-12,309 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$18.41 - $28.0 $219,079 - $333,200	-11,900 Reduced 49.16%	12,309 $237,000
Q2 2019 Aug 06, 2019	BUY	$28.97 - $48.21 $701,334 - $1.17 Million	24,209 New	24,209 $715,000
Q4 2018 Feb 12, 2019	SELL	$33.0 - $60.04 $198,000 - $360,240	-6,000 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$56.15 - $73.9 $336,900 - $443,400	6,000 New	6,000 $369,000
Q1 2018 May 11, 2018	SELL	$51.15 - $61.0 $838,860 - $1 Million	-16,400 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$50.85 - $65.1 $506,262 - $648,135	9,956 Added 154.5%	16,400 $980,000
Q3 2017 Nov 20, 2017	BUY	$48.6 - $60.1 $313,178 - $387,284	6,444	6,444 $313,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.